While nuclear hormone receptor (NHR)-TFs (e.g., the estrogen, progesterone, and steroid receptors) belong to the most common therapeutic targets in cancer (e.g., in breast and prostate carcinoma, lymphoid malignancies, and MM, respectively), non-NHR-TFs (among them p53 and c-MYC) have been widely considered as “undruggable”. The gene discussed is MYC; the disease is Miyoshi myopathy.